Wegovy (semaglutide) and Mounjaro (tirzepatide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Victoza (liraglutide) and Ozempic (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including FTO, GLP1R, and MC4R — that apply regardless of which compound is prescribed.

Mounjaro (tirzepatide) and Wegovy (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

There is no FDA-approved "GLP-3" as of April 2026. Searches for it usually reflect interest in triple-agonist investigational compounds (retatrutide) or confusion with dual-agonist tirzepatide. This article explains what is real and the GLP-1 pathway genetics.

GLP-1 and GLP-2 are distinct gut peptides from the same proglucagon precursor. GLP-1 receptor agonists treat type 2 diabetes and obesity. GLP-2 (teduglutide / Gattex) treats short bowel syndrome. This article explains the biology, the drugs, and the GLP-1 pathway genetics.

Tirzepatide and semaglutide are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Semaglutide and tirzepatide are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Retatrutide and tirzepatide are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Zepbound (tirzepatide) and Mounjaro (tirzepatide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Mounjaro (tirzepatide) and Zepbound (tirzepatide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Zepbound (tirzepatide) and Ozempic (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Ozempic (semaglutide) and Mounjaro (tirzepatide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Mounjaro (tirzepatide) and Ozempic (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Zepbound (tirzepatide) and Wegovy (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Wegovy (semaglutide) and Zepbound (tirzepatide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Wegovy (semaglutide) and Ozempic (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including FTO, GLP1R, and MC4R — that apply regardless of which compound is prescribed.

Ozempic (semaglutide) and Wegovy (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including FTO, GLP1R, and MC4R — that apply regardless of which compound is prescribed.